Table 1 Comparison of clinical and molecular characteristics of de novo AML patients according to ETS2
Variable | AML (TCGA dataset) | ||
|---|---|---|---|
ETS2high (n = 89) | ETS2low (n = 90) | P | |
Median age, year (range) | 0.01 | ||
Median | 61 | 54.5 | |
Range | (18–88) | (22–82) | |
Age group, n (%) | 0.004 | ||
<60 | 38 | 58 | |
≥60 | 51 | 32 | |
WBC count, X109/L | 0.05 | ||
Median | 33.2 | 12.2 | |
Range | 0.6–297.4 | 0.4–202.7 | |
BM blasts (%) | 0.6 | ||
Median | 74 | 72 | |
Range | 32–100 | 30–100 | |
PB blasts (%) | 0.01 | ||
Median | 49 | 25 | |
Range | 0–98 | 0–97 | |
FAB subtype, no (%) | |||
M0 | 14 | 2 | 0.001 |
M1 | 30 | 14 | 0.005 |
M2 | 18 | 22 | 0.59 |
M3 | 0 | 16 | <0.001 |
M4 | 16 | 19 | 0.6 |
M5 | 6 | 15 | 0.04 |
M6 | 1 | 1 | 1 |
Others | 4 | 1 | 0.21 |
FLT3-ITD, n (%) | 0.01 | ||
Present | 25 | 12 | |
Absent | 64 | 78 | |
NPM1 (no FLT3-ITD), n (%) | 0.33 | ||
Mutated | 12 | 17 | |
Wild-type | 77 | 73 | |
CEBPA, n (%) | 0.24 | ||
Single mutated | 3 | 5 | |
Double mutated | 1 | 4 | |
Wild-type | 85 | 81 | |
MLL-PTD, n (%) | 0.33 | ||
Mutated | 6 | 3 | |
Wild-type | 83 | 87 | |
IDH1, n (%) | 0.58 | ||
Mutated | 9 | 7 | |
Wild-type | 80 | 83 | |
IDH2, n (%) | 0.78 | ||
Mutated | 9 | 8 | |
Wild-type | 80 | 82 | |
RUNX1, n (%) | 0.08 | ||
Mutated | 12 | 5 | |
Wild-type | 77 | 85 | |
DNMT3A, n (%) | 0.21 | ||
R882 mutated | 16 | 7 | |
Non-R822 mutated | 9 | 11 | |
Wild-type | 64 | 72 | |
TP53, n (%) | 0.016 | ||
Mutated | 12 | 3 | |
Wild-type | 77 | 87 | |
ERG expression, n (%) | 0.16 | ||
High | 49 | 40 | |
Low | 40 | 50 | |
BAALC expression, n (%) | 0.07 | ||
High | 50 | 39 | |
Low | 39 | 51 | |
MN1 expression, n (%) | 0.04 | ||
High | 51 | 38 | |
Low | 38 | 52 | |
miR155HG expression, n (%) | <0.001 | ||
High | 56 | 33 | |
Low | 33 | 57 | |
WT1 expression, n (%) | 0.009 | ||
High | 53 | 36 | |
Low | 36 | 54 | |